| Literature DB >> 35696226 |
Ming-Hsien Lin1, Chi-Feng Hung2, Hsin-Ching Sung3,4, Shih-Chun Yang5, Huang-Ping Yu6,7, Jia-You Fang6,8,9.
Abstract
Resveratrol has been extensively reported as a potential compound to treat some skin disorders, including skin cancer, photoaging, allergy, dermatitis, melanogenesis, and microbial infection. There has been an increasing interest in the discovery of cosmetic application using resveratrol as the active ingredient because of its anti-aging and skin lightening activities. The naturally occurring derivatives of resveratrol also exert a beneficial effect on the skin. There are four groups of resveratrol derivatives, including hydroxylated compounds, methoxylated compounds, glycosides, and oligomers. The major mechanism of resveratrol and its derivatives for attenuating cutaneous neoplasia, photoaging and inflammation, are related with its antioxidative activity to scavenge hydroxyl radical, nitric oxide and superoxide anion. A systematic review was conducted to describe the association between resveratrol-related compounds and their benefits on the skin. Firstly, the chemical classification of resveratrol and its derivatives was introduced. In this review the cases which were treated for different skin conditions by resveratrol and the derivatives were also described. The use of nanocarriers for efficient resveratrol skin delivery is also introduced here. This review summarizes the cutaneous application of resveratrol and the related compounds as observed in the cell-based, animal-based and clinical models. The research data in the present study relates to the management of resveratrol for treating skin disorders and suggesting a way forward to achieve advancement in using it for cosmetic and dermatological purpose.Entities:
Mesh:
Substances:
Year: 2021 PMID: 35696226 PMCID: PMC9261849 DOI: 10.38212/2224-6614.1151
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Fig. 1The chemical structures of resveratrol and its naturally occurring derivatives discussed in this review. There are four groups of resveratrol derivatives, including hydroxylated compounds, methoxylated compounds, glycosides, and oligomers. The major oligomers with bioactivities on skin are dimmers, trimers, and tetramers.
Fig. 2The structures of nanocarriers used for cutaneous delivery of resveratrol and its naturally occurring derivatives. These nanosystems include liposomes, niosomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanoemulsions, polymeric nanoparticles, and dendrimers. The detailed description of the structures of these nanocarriers is shown in the text.
Anti-skin cancer activity of resveratrol and its derivatives.
| Compound | Experimental model | Cell or animal type | Outcomes offered by the compound | Reference |
|---|---|---|---|---|
| Resveratrol | Colo-16 cells | Cell growth inhibition via Wnt signaling | [ | |
| Resveratrol | Ca3/7 cells | Synergistic effect with ursolic acid | [ | |
| Resveratrol | ICR mouse | Tumor suppression by COX-2 inhibition | [ | |
| Resveratrol | ICR mouse | Tumor suppression via NF-κB and AP-1 pathways | [ | |
| Resveratrol | Albino mouse | Tumor suppression via PI3K and protein kinase B regulation | [ | |
| Resveratrol | B16–F10 and A375 cells | Apoptosis via PI3K and protein kinase B regulation | [ | |
| Resveratrol | DM738 and DM443 cells | Synergistic effect with temozolomide | [ | |
| ε-Viniferin and pallidol | HT-144 and SKMEL-28 cells | ε-Viniferin displayed a greater melanoma inhibition than resveratrol and pallidol | [ | |
| ε-Viniferin and labruscol | HT-144 and SKMEL-28 cells | Melanoma inhibition via cell cycle blocking in | [ | |
| Resveratrol in liposomes | SKMEL-28 and Colo-38 cells | Ultradeformable liposomes enhanced cytotoxicity and percutaneous permeation | [ | |
| Resveratrol in polymeric nanoparticles | B16–F10 cells and mouse | Nanoparticles enhanced cytotoxicity and | [ |
AP-1; activator protein-1; COX-2, cyclooxygenase-2; DMBA, 7,12-dimethylbenz[a]anthracene; NF-κB, nuclear factor-κB; PI3K, phos-phatidylinositol-3-kinase; SCC, squamous cell carcinoma.
Fig. 3The skin diseases that can be ameliorated by resveratrol and its naturally occurring derivatives in cell- or animal-based studies. The possible signaling pathways for the treatment of these skin disorders are summarized in this figure. Resveratrol and its analogs demonstrate antioxidant, anticancer, antiaging, anti-inflammatory, anti-melanogenesis, and antimicrobial impacts for skin application.
Fig. 4The morphologies and features of psoriasis and atopic dermatitis skins. Typical histologic features of psoriasis includes epidermal hyperplasia with elongated rete ridges, a less discrete epidermal granular layer, parakeratosis, and leukocyte infiltration of the viable skin. Dermatitis is an inflammatory skin disease characterized by presence of erythema, edema, vesicles, and lichenification. The effects of resveratrol and its analogs on psoriasis and dermatitis for ameliorating the signs and symptoms are summarized in this figure.
Extrinsic and intrinsic aging treated by resveratrol and its derivatives.
| Compound | Experimental model | Cell or animal type | Outcomes offered by the compound | Reference |
|---|---|---|---|---|
| Resveratrol | Pig | Resveratrol showed a satisfied skin absorption to exert antioxidative activity | [ | |
| Resveratrol | Human | Topically applied resveratrol mainly located in SC layer | [ | |
| Resveratrol | HaCaT cells | Resveratrol increased cell survival and attenuated ROS in UVB-treated cells | [ | |
| Resveratrol | Hairless mouse | Resveratrol downregulated cell cycle regulatory proteins | [ | |
| Resveratrol | Hairless mouse | Resveratrol downregulated survivin | [ | |
| Pterostilbene | HaCaT cells | Resveratrol attenuated UVB-evoked cell death and ROS generation via Nrf2 signaling | [ | |
| Pterostilbene | Hairless mouse | Pterostilbene showed superior oxidative damage inhibition than resveratrol | [ | |
| Polydatin | HaCaT cells and nude mouse | Polydatin as the antioxidant and sunscreen to inhibit UVB-induced skin damage | [ | |
| Oligomers | Dermal fibroblasts | (−)-Hopeaphenol, vaticanol C, stenophyllol C exhibited significant inhibition on MMP-1 | [ | |
| Resveratrol in transfersomes and ethosomes | HaCaT cells | Ethosomes reduced ROS production and increased resveratrol absorption | [ | |
| Resveratrol in transfersomes | Strat-M membrane | Transfersomes increased resveratrol delivery | [ | |
| Resveratrol in SLNs and NLCs | Dermal fibroblasts | NLCs showed greater ROS reduction than SLNs | [ | |
| Resveratrol | Resveratrol reversed skin thinning via | [ | ||
| Resveratrol | Human | Resveratrol increased skin hydration by 2-fold | [ | |
| Resveratrol and procyanidins | Human | Skin moisturization and elasticity were increased by dietary supplementation | [ | |
| Pterostilbene | Human | The skin moisturization and elasticity were improved with no adverse effects | [ | |
| Resveratrol in SLNs, NLCs, and nanoemulsions | Human | An increase of skin hydration was detected with a tendency of SLNs > NLCs > nanoemulsions | [ |
IL, interleukin; MMP-1, matrix metalloproteinase-1; NLCs, nanostructured lipid carriers; Nrf2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; SC, stratum corneum; SLNs, solid lipid nanoparticles; Sod: superoxide dismutase; UVB, ultraviolet B.
Anti-inflammatory activity of resveratrol and its derivatives.
| Compound | Experimental model | Cell or animal type | Outcomes offered by the compound | Reference |
|---|---|---|---|---|
| Resveratrol | Human keratinocytes | Resveratrol restrained keratinocyte proliferation via aquaporin 3 inhibition | [ | |
| Resveratrol | Balb/c mouse | Oral resveratrol alleviated the severity of scaling and skin redness | [ | |
| Resveratrol | Balb/c mouse | Topical resveratrol reduced skin thickness and edema | [ | |
| Resveratrol-enriched rice | NC/Nga mouse | The rice reduced scratching frequency and dermatitis severity | [ | |
| Resveratrol | Balb/c mouse | Oral resveratrol reduced skin thickness and immune response | [ | |
| Resveratrol | Balb/c mouse | Oral resveratrol downregulated Th2-type cytokines | [ | |
| Pterostilbene | C57BL/6 mouse | Oral pterostilbene attenuated erythema and immune cell infiltration | [ | |
| Polydatin | Human keratinocytes | Polydatin inhibited ERK phosphorylation and NF-κB activation | [ | |
| Polydatin | HaCaT cells | Polydatin inhibited MCP-1, TNF-α, and IL-6 | [ | |
| Polydatin | HaCaT cells | Polydatin inhibited TNF-α, IL-6, and IL-8 | [ | |
| Resveratrol and quercetin in liposomes | Dermal fibroblasts and CD-1 mouse | The liposomes increased cellular uptake and reduced edema and neutrophil infiltration | [ | |
| Resveratrol in niosomes | Wistar rat | The enhanced resveratrol skin absorption with reduced edema | [ | |
| Resveratrol and DHA in SLNs | HaCaT cells | DHA could synergize with resveratrol in SLNs to inhibit cytokine expression | [ | |
| Resveratrol in SLNs | Mouse | SLNs inhibited skin edema | [ |
AD, atopic dermatitis; DHA, docosahexaenoic acid; ERK, extracellular signal-regulated kinase; IL, interleukin; MCP-1, monocyte chemotactic protein-1; NF-κB, nuclear factor-κB; SLNs, solid lipid nanoparticles; TNF-α, tumor necrosis factor-α.
Fig. 5The pathogenic mechanisms of skin hyperpigmentation. Melanin synthesis begins with catalysation of the substrates phenylalanine and tyrosine to produce L-DOPA via tyrosinase. The pathways are then divided into eumelanogenesis or pheomelanogenesis. The other melanogenic enzyme is TRP-1 for eumelanogenesis. Resveratrol is a direct tyrosinase inhibitor. It also can inhibit melanogenic enzymes.
Hypopigmenting activity of resveratrol and its derivatives.
| Compound | Experimental model | Cell or animal type | Outcomes offered by the compound | Reference |
|---|---|---|---|---|
| Resveratrol | Cell-based tyrosinase inhibition | HEK293 cells | Resveratrol was effective to inhibit human tyrosinase | [ |
| Resveratrol | Human | Resveratrol inhibited sunburn cell formation | [ | |
| Oxyresveratrol | Cell-based tyrosinase inhibition | B16 cells | Oxyresveratrol was effective to inhibit mushroom and murine tyrosinases | [ |
| Oxyresveratrol and 4′-prenyloxyresveratrol | Mushroom tyrosinase | Oxyresveratrol and 4′-prenyloxyresveratrol from mulberry inhibited tyrosinase | [ | |
| Resveratrol and oxyresveratrol | Cell-based 3D reconstituted skin | MelanoDerm® | Oxyresveratrol showed higher melanin inhibition than resveratrol | [ |
| Resveratrol and piceatannol | Mushroom tyrosinase and B16 cells | Piceatannol showed higher tyrosinase inhibition than resveratrol | [ | |
| Polydatin | Cell-based tyrosinase inhibition | Melan-a cells | Polydatin inhibited melanin content and tyrosinase | [ |
| Polydatin | Mushroom tyrosinase | Polydatin showed higher tyrosinase inhibition than resveratrol | [ | |
| Resveratrol and gnectin C | Cell-based tyrosinase inhibition | B16 cells | Resveratrol and gnectin showed a comparable tyrosinase inhibition | [ |
| α-Viniferin | Cell-based tyrosinase inhibition and | Melan-a cells and human | α-Viniferin decreased melanin index in the patients with melasma | [ |
| Resveratrol in nanoparticles | Guinea pig | The nanoparticles decreased melanin granules in skin | [ | |
| Resveratrol in SLNs | Mushroom tyrosinase | Resveratrol loaded in SLNs promoted tyrosinase inhibition | [ |
SLNs, solid lipid nanoparticles; UV, ultraviolet.
Antimicrobial activity of resveratrol and its derivatives.
| Compound | Experimental model | Microbial or animal type | Outcomes offered by the compound | Reference |
|---|---|---|---|---|
| Resveratrol | Dermatophytes | Resveratrol effectively retarded dermatophyte growth | [ | |
| Resveratrol | HSV | Resveratrol mitigated skin lesion caused by HSV | [ | |
| Oxyresveratrol | HSV | Oxyresveratrol delayed the development of skin lesion caused by HSV | [ | |
| Pterostilbene | MRSA | Pterostilbene showed superior MRSA growth inhibition than resveratrol | [ | |
| Resveratrol and gallic acid in liposomes | Skin pathogens | Liposomes improved antimicrobial activity of resveratrol | [ |
HSV, herpes simplex virus; MRSA, methicillin-resistant Staphylococcus aureus.